海王生物(000078) - 2023 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2023 was ¥8,686,586,186.99, a decrease of 19.82% compared to the same period last year[4] - Net profit attributable to shareholders was ¥803,351.67, down 95.58% year-on-year, while the net profit after deducting non-recurring gains and losses was a loss of ¥11,474,745.84, a decline of 178.31%[4] - Total operating revenue for Q3 2023 was CNY 28,640,393,734.42, a decrease of 1.08% from CNY 28,955,751,861.94 in Q3 2022[16] - Net profit for Q3 2023 was CNY 186,009,299.78, a decline of 14.74% compared to CNY 218,156,601.74 in Q3 2022[17] - Earnings per share for Q3 2023 were CNY 0.0322, down from CNY 0.0480 in Q3 2022[17] Cash Flow - The operating cash flow net amount for the year-to-date was ¥174,848,146.77, reflecting a significant decrease of 72.33%[4] - The net cash flow from operating activities for the current period is ¥174,848,146.77, a decrease of 72.25% compared to ¥631,812,732.98 in the previous period[19] - Cash inflow from operating activities totaled ¥30,531,485,937.02, down 7.99% from ¥33,128,404,926.38 in the previous period[19] - Cash outflow from operating activities was ¥30,356,637,790.25, a decrease of 6.58% compared to ¥32,496,592,193.40 in the previous period[19] - Cash inflow from investing activities was ¥51,405,578.42, significantly lower than ¥231,046,683.67 in the previous period, marking an 77.76% decline[19] - The net cash flow from investing activities was -¥283,781,333.03, an improvement from -¥423,678,767.84 in the previous period[19] - Cash inflow from financing activities reached ¥17,890,602,812.02, an increase of 81.56% compared to ¥9,857,263,109.04 in the previous period[20] - The net cash flow from financing activities was -¥131,026,726.28, an improvement from -¥828,218,509.32 in the previous period[20] - The ending balance of cash and cash equivalents was ¥722,544,418.84, up from ¥359,743,994.20 in the previous period[20] Assets and Liabilities - Total assets at the end of the reporting period were ¥36,011,587,263.92, a slight decrease of 0.66% from the end of the previous year[5] - Total liabilities as of Q3 2023 amounted to CNY 29,825,392,793.37, a slight decrease from CNY 30,141,845,242.23 in the previous year[16] - The company reported a total of CNY 31,420,783,965.74 in current assets as of September 30, 2023, slightly down from CNY 31,524,548,826.78 at the beginning of the year[13] Shareholder Information - The company has 141,369 common stock shareholders as of the report date[10] - The largest shareholder, Shenzhen Haiwang Group, holds 44.22% of the shares, amounting to 1,216,445,128 shares[10] - The total number of shares held by the top 10 shareholders includes significant pledges, with Shenzhen Haiwang Group having 1,214,318,870 shares pledged[10] Investment and Income - Investment income increased by 69.05% year-on-year, mainly due to gains from the disposal of subsidiaries[9] - The company experienced a 252.95% increase in non-operating income year-on-year, primarily from increased penalty interest on litigation receivables[9] - The company reported an investment income of CNY 25,825,105.42 for Q3 2023, up from CNY 15,276,341.79 in Q3 2022[16] Operational Metrics - Total operating costs for Q3 2023 were CNY 28,340,184,524.32, down 1.07% from CNY 28,646,453,716.97 in the same period last year[16] - Research and development expenses for Q3 2023 were CNY 37,110,222.28, slightly down from CNY 37,669,721.48 in Q3 2022[16] - Financial expenses increased to CNY 587,737,888.85 in Q3 2023, compared to CNY 467,180,747.40 in the same period last year[16] Inventory and Receivables - Accounts receivable increased to CNY 19,993,419,545.06 from CNY 18,812,836,510.75, reflecting a growth of approximately 6.3%[13] - Inventory decreased to CNY 3,471,716,571.54 from CNY 4,193,040,385.13, indicating a decline of about 17.2%[13]